According to Morgan Stanley and Goldman Sachs analyst reports, sell-side consensus expects Oscar Health ($OSCR) revenue growth to be negative in 2026 due to anticipated regulatory changes impacting Medicaid redeterminations and potential loss of key state contracts. Analysts also cite increased competitive pressures in the health insurance marketplace and slower member enrollment growth as contributing factors. These headwinds are expected to reduce premium revenues, directly affecting OSCR's top-line performance and potentially impacting related healthcare and digital health crypto tokens exposed to insurance sector trends (sources: Morgan Stanley Healthcare Quarterly, Goldman Sachs Oscar Health Equity Research, May 2024).